NO20064473L - Stabilised supersaturated solid solutions of steroidal drugs - Google Patents

Stabilised supersaturated solid solutions of steroidal drugs

Info

Publication number
NO20064473L
NO20064473L NO20064473A NO20064473A NO20064473L NO 20064473 L NO20064473 L NO 20064473L NO 20064473 A NO20064473 A NO 20064473A NO 20064473 A NO20064473 A NO 20064473A NO 20064473 L NO20064473 L NO 20064473L
Authority
NO
Norway
Prior art keywords
solid solutions
supersaturated solid
steroidal drugs
lipophilic
silica
Prior art date
Application number
NO20064473A
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064473(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20064473L publication Critical patent/NO20064473L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Den foreliggende oppfinnelse angår et farmasøytisk preparat med forbedret oppløsning av lipofile legemidler i et vandig medium. Det har vist seg at farmasøytiske preparater som omfatter et pulver av lipofile forbindelser, slik som hormoner og steroider (f.eks. drospirenon og estradiolvalerat), i molekylær dispergert form sammen med en bærer med et spesifikt overflateareal på minst 250 m2/g , slik som silikadioksid, f.eks. silikadioksid markedsført under navnet Aeroperl(, har forbedret oppløsningsegenskapene av det lipofile legemiddel.
NO20064473A 2004-03-10 2006-10-02 Stabilised supersaturated solid solutions of steroidal drugs NO20064473L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
NO20064473L true NO20064473L (no) 2006-10-10

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064473A NO20064473L (no) 2004-03-10 2006-10-02 Stabilised supersaturated solid solutions of steroidal drugs

Country Status (33)

Country Link
US (1) US8715735B2 (no)
EP (2) EP1765290B1 (no)
JP (1) JP5006185B2 (no)
KR (1) KR101210695B1 (no)
CN (1) CN1984644B (no)
AR (1) AR048500A1 (no)
AT (1) ATE442131T1 (no)
AU (1) AU2005221403B8 (no)
BR (1) BRPI0507342A (no)
CA (1) CA2558582C (no)
CR (1) CR8630A (no)
DE (1) DE602005016551D1 (no)
DK (1) DK1765290T3 (no)
EA (1) EA012746B1 (no)
EC (1) ECSP066902A (no)
ES (2) ES2390406T3 (no)
GT (1) GT200500045A (no)
HK (1) HK1103660A1 (no)
HR (1) HRP20090614T1 (no)
IL (1) IL177894A0 (no)
MY (1) MY142989A (no)
NO (1) NO20064473L (no)
NZ (1) NZ549793A (no)
PA (1) PA8626101A1 (no)
PE (1) PE20060016A1 (no)
PL (1) PL1765290T3 (no)
PT (1) PT1765290E (no)
RS (1) RS51076B (no)
SI (1) SI1765290T1 (no)
SV (1) SV2005002044A (no)
TW (1) TWI345986B (no)
UY (1) UY28803A1 (no)
WO (1) WO2005087199A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
CN101237851B (zh) * 2005-06-16 2013-09-18 沃纳奇尔科特有限责任公司 用于阴道给药的雌激素组合物
EP2023899A1 (en) * 2006-05-10 2009-02-18 Evonik Degussa GmbH Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
AR065439A1 (es) 2007-02-23 2009-06-10 Gilead Sciences Inc Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
US20100119601A1 (en) * 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
BRPI0908477A2 (pt) * 2008-02-13 2018-03-27 Bayer Schering Pharma Ag sistema de distribuição de medicamento contendo estradiol
EP2251038B1 (en) * 2008-03-11 2017-05-10 ASKA Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
ES2553897T3 (es) 2008-05-02 2015-12-14 Gilead Sciences, Inc. El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
WO2010042930A1 (en) * 2008-10-10 2010-04-15 Ahmed Salah U Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
US20120064166A1 (en) * 2009-02-18 2012-03-15 Bayer Pharma Aktienesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
CA2992923C (en) 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
ES2898682T3 (es) * 2017-02-14 2022-03-08 Dsm Ip Assets Bv Formulaciones estables en almacenamiento
BR112019016678B1 (pt) * 2017-02-14 2023-12-05 Dsm Ip Assets B.V Formulações dispersíveis em água, dispersão aquosa e produtos alimentícios
CN110013467B (zh) 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
DK0492007T3 (da) * 1990-11-29 1995-06-26 Faulding F H & Co Ltd Fremgangsmåde til fremstilling af væskepåfyldte pulvere
DE4326240A1 (de) 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
HU227207B1 (en) 1999-08-31 2010-11-29 Bayer Schering Pharma Ag Use of a pharmaceutical combination of ethinylestradiol and drospirenone for producing pharmaceutical compositions having contraceptive activity
KR100913910B1 (ko) 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
OA12625A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1551415B1 (en) 2002-09-05 2009-12-23 Pantarhei Bioscience B.V. Oral pharmaceutical composition comprising 15-hydroxytestosterone and its analogues
PT1558265E (pt) 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh Rotkr Socke
EP1601347A1 (en) * 2003-02-19 2005-12-07 LifeCycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion

Also Published As

Publication number Publication date
SV2005002044A (es) 2005-11-04
GT200500045A (es) 2005-10-31
SI1765290T1 (sl) 2010-01-29
CN1984644A (zh) 2007-06-20
HK1103660A1 (en) 2007-12-28
NZ549793A (en) 2010-06-25
ES2332229T3 (es) 2010-01-29
CA2558582A1 (en) 2005-09-22
IL177894A0 (en) 2006-12-31
HRP20090614T1 (hr) 2009-12-31
CA2558582C (en) 2013-07-16
EP2087883B1 (en) 2012-07-25
BRPI0507342A (pt) 2007-07-03
AU2005221403A1 (en) 2005-09-22
PL1765290T3 (pl) 2010-02-26
KR20060132999A (ko) 2006-12-22
WO2005087199A3 (en) 2009-01-15
US20050207990A1 (en) 2005-09-22
JP5006185B2 (ja) 2012-08-22
US8715735B2 (en) 2014-05-06
UY28803A1 (es) 2005-10-31
WO2005087199A8 (en) 2007-03-29
EP1765290A2 (en) 2007-03-28
CR8630A (es) 2007-06-06
DE602005016551D1 (de) 2009-10-22
CN1984644B (zh) 2010-12-08
PT1765290E (pt) 2009-11-23
ATE442131T1 (de) 2009-09-15
ECSP066902A (es) 2006-12-20
EA200601588A1 (ru) 2007-02-27
EA012746B1 (ru) 2009-12-30
ES2390406T3 (es) 2012-11-12
EP2087883A1 (en) 2009-08-12
PE20060016A1 (es) 2006-02-16
DK1765290T3 (da) 2009-11-02
TW200600116A (en) 2006-01-01
PA8626101A1 (es) 2006-07-03
AU2005221403B2 (en) 2009-12-10
AU2005221403B8 (en) 2010-01-07
MY142989A (en) 2011-02-14
KR101210695B1 (ko) 2012-12-11
WO2005087199A2 (en) 2005-09-22
TWI345986B (en) 2011-08-01
JP2007528389A (ja) 2007-10-11
RS51076B (sr) 2010-10-31
EP1765290B1 (en) 2009-09-09
AR048500A1 (es) 2006-05-03

Similar Documents

Publication Publication Date Title
NO20064473L (no) Stabilised supersaturated solid solutions of steroidal drugs
DK1748756T3 (da) Præparater som omfatter drospirenon der er molekylært dispergeret
Formariz et al. Structure and viscoelastic behavior of pharmaceutical biocompatible anionic microemulsions containing the antitumoral drug compound doxorubicin
BRPI0512177A (pt) formulação de liberação modificada de memantina
WO2006039022A3 (en) Controlled regional oral delivery
MX2009007742A (es) Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
ATE464054T1 (de) Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
BRPI0717509A2 (pt) sistema de liberação controlada para aplicação nasal de neurotransmissores
HK1120417A1 (en) Stable nanoparticle formulations
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
NO20065657L (no) Filmformet ostriol-inneholdende medikament for oral administrasjon
Kalava et al. Physicochemical characterization and dissolution properties of cinnarizine solid dispersions
UA87838C2 (ru) Стабилизированные перенасыщенные твердые растворы липофильных лекарствнных средств
CY1109564T1 (el) Σταθεροποιημενα υπερκορεσμενα στερεα λιποφιλων φαρμακων
Li et al. Cosolubilization of non-polar drugs in polysorbate 80 solutions
Saxena et al. NOVEL STRATEGY FOR AMPLIFICATION OF DRUG SOLUBILITY BY SOLID DISPERSION PELLETS STRATEGY
TH75689A (th) ของแข็งชนิดอิ่มตัวยิ่งยวดที่ผ่านการทำให้เสถียรของยาชนิดลิโพฟิลิก
TW200609000A (en) Molecular dispersions of drospirenone
Hajare MATRIX IMPURITY, DISREGARDS IMPURITY, SPECIFIED IMPURITY ASSOCIATED UNDETECTABLE IMPURITY: MONOGRAPH
BR112017021995A2 (pt) formulação farmacêutica compreendendo drogas de baixa fusão e altamente lipofílicas e método de melhora da dissolução
TH171506A (th) องค์ประกอบทางเภสัชกรรมขนาดยาต่ำ
TH118582B (th) องค์ประกอบเชิงเภสัชกรรมและวิธีการรักษาสำหรับการคุมกำเนิดฉุกเฉิน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application